This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 10 No. 4, October 2003
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dubik, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dubik, M.
Related Collections
Right arrow Community Pediatrics
Right arrow Infectious Diseases

AAP Grand Rounds 10:52-53 (2003)
© 2003 American Academy of Pediatrics

COMMUNITY HEALTH

Clindamycin Treatment of Community-acquired MR and MS Staph A Invasive Infections

Source: Martinez-Aguilar G, Hammerman WA, Mason EO, et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22:593–598.[Medline]

The first 20% of the full text of this article appears below.

The authors report a retrospective medical record review of 99 patients admitted to Texas Children’s Hospital with deep-seated infections due to Staphylococcus aureus: 46 (median age 3.5 years, range 2 months to 18.6 years) with community-acquired methicillin-resistant S aureus (CA-MRSA) and 53 (median age 4.8 years, range 3 months to 19.8 years) with community-acquired methicillin-susceptible S aureus (CA-MSSA). Patients with an underlying illness predisposing to frequent hospitalizations were excluded. The authors compared the outcome of therapy for MRSA with that of MSSA invasive infections in children treated with clindamycin, vancomycin or beta-lactam . . . [Full Text of this Article]

Mike Dubik, MD, FAAP
Pediatrics, Naval Medical Center, San Diego, CA

 



This article has been cited by other articles:


Home page
 AAP Grand RoundsHome page
B. Robbins
MRSA Outnumbers MSSA for Common Skin Infections Acquired in the Community
AAP Grand Rounds, July 1, 2006; 16(1): 77 - 78.
[Full Text] [PDF]

Home page
 AAP Grand RoundsHome page
M. H. Rathore
To Decide if Clindamycin Is Optimal Drug for MRSA, Request a D-Test
AAP Grand Rounds, February 1, 2004; 11(2): 18 - 19.
[Full Text] [PDF]